AI Article Synopsis

  • The study investigates noninvasive imaging techniques, specifically high-resolution nerve ultrasound (HRUS) and corneal confocal microscopy (CCM), to predict treatment responses in patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).
  • A cohort of 17 CIDP patients was monitored over 18 months using CCM and HRUS to assess nerve degeneration and immune cell infiltration, along with skin biopsies and sensory testing.
  • Key findings suggest that certain measurements from CCM and HRUS can accurately identify patients experiencing disease progression, which could guide treatment strategies.

Article Abstract

Background: One of the main goals of novel, noninvasive imaging techniques like high-resolution nerve ultrasound (HRUS) and corneal confocal microscopy (CCM) is the prediction of treatment response for patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).

Methods: A total of 17 patients with CIDP were examined prospectively at baseline and every 9 months over a period of 18 months using CCM to quantify corneal nerve degeneration markers and immune cell infiltration as well as HRUS to detect changes of the cross-sectional area (CSA) of the peripheral nerves. Additionally, skin biopsy of the distal and proximal leg as well as quantitative sensory testing were performed at the first follow-up visit.

Results: A value of more than 30 total corneal cells/mm in CCM at baseline identified patients with clinical progression with a sensitivity/specificity of 100% in our cohort. Corneal nerve fiber density and length remained low and stable over the study period and intra-epidermal fiber density was markedly reduced in the majority of the patients. Furthermore, an increase in Bochum ultrasound score (BUS), which summarizes the CSA of the ulnar nerve in Guyons' canal, the ulnar nerve in the upper arm, the radial nerve in the spiral groove and the sural nerve between the gastrocnemius muscle, and a maximum BUS of 4 at study initiation identified patients with disease progression (sensitivity 80%, specificity 88%).

Conclusions: BUS and corneal total cell infiltration seem to represent early markers for clinical progression in CIDP, thus having the potential to identify at-risk patients and impact treatment decisions.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6582292PMC
http://dx.doi.org/10.1177/1756286419855485DOI Listing

Publication Analysis

Top Keywords

clinical progression
12
markers clinical
8
chronic inflammatory
8
inflammatory demyelinating
8
demyelinating polyradiculoneuropathy
8
corneal nerve
8
cell infiltration
8
identified patients
8
fiber density
8
ulnar nerve
8

Similar Publications

Metastasis is a major cause of poor prognosis of pancreatic cancer. Exosomes (Exos) regulate cancer progression by modulating macrophage polarization. This study aimed to investigate the effects of cancer-associated fibroblast (CAF)-released Exos on macrophage polarization in pancreatic cancer and the molecular mechanisms.

View Article and Find Full Text PDF

This retrospective study aimed to evaluate the efficacy and safety of PBVD (pegylated liposomal doxorubicin [PLD], bleomycin, vinblastine, and dacarbazine) in the first-line treatment of classical Hodgkin lymphoma (cHL) patients with cardiovascular risk factors. Overall, 84 patients (53 had stage I-II and 31 had stage III-IV disease) received PBVD. The median PLD treatment duration was 16 weeks (interquartile range [IQR]: 8-24) for stage I-II and 24 weeks (IQR: 12-24) for stage III-IV.

View Article and Find Full Text PDF

Patients participating in clinical trials are highly selected and may not represent the general population. The pivotal study of teclistamab (MajesTEC-1), a B-cell maturation antigen (BCMA)xCD3 bispecific antibody, demonstrated impressive response rates and progression free survival in relapsed/refractory multiple myeloma (RRMM) with acceptable toxicity. We performed a retrospective study of 58 patients treated as standard of care at four US academic centers to determine how these results translated to the real-world.

View Article and Find Full Text PDF

Iliac Crest Bone Graft and Fascia Lata Free Flap for Rescue of Mandibular Osteoradionecrosis.

Otolaryngol Head Neck Surg

January 2025

Section of Facial Plastic and Microvascular Surgery, Cleveland Clinic, Cleveland, Ohio, USA.

Objective: Describe the use, indications, and outcomes of iliac crest bone graft (ICBG) with concomitant anterolateral thigh fascia lata (ALTFL) rescue flap for the management of mandibular osteoradionecrosis (ORN).

Study Design: Retrospective chart review.

Setting: Single institution.

View Article and Find Full Text PDF

Autograft composition and outcome-towards an optimal graft?

Cytotherapy

December 2024

Department of Medicine, Kuopio University Hospital, Kuopio, Finland. Electronic address:

The amount of CD34 cells has been for decades the most important marker of autologous graft quality, but other graft cells, including various lymphocyte subsets, have gained some interest. This review attempts to summarize what is known about autograft cellular composition regarding post-transplant outcomes. The amount of CD34 cells in the graft is associated with tempo of platelet recovery.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!